The secondary endpoints , including a change in the frequency of chest pain ( -3.70.5 vs -1.90.6 , respectively , p = 0.029 ) , a change in the chest pain severity scale ( -2.80.4 vs -1.10.4 , respectively , p = 0.003 ) , and the proportion of chest pain-free patients ( 76.0 % vs 33.3 % , respectively , p = 0.003 ) also significantly favoured cilostazol .